Citius Oncology, Inc. (CTOR)
| Market Cap | 159.94M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.58M |
| Shares Out | 78.37M |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | 99.50 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 481,777 |
| Open | 2.030 |
| Previous Close | 1.990 |
| Day's Range | 1.990 - 2.196 |
| 52-Week Range | 0.551 - 6.190 |
| Beta | 3.01 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Aug 12, 2025 |
About CTOR
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc. [Read more]
Full Company ProfileNews
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch
Proprietary model informs targeted sales and marketing strategies with feedback loop that augments precision and impact of targeting and engagement CRANFORD, N.J. , Aug. 22, 2025 /PRNewswire/ -- Citiu...
Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
LYMPHIR commercial availability planned for the fourth quarter of 2025 $12.5 million in gross financings raised during the quarter by Citius Pharmaceuticals, with an additional $9 million raised by Ci...
Citius Oncology Announces Closing of $9.0 Million Public Offering
CRANFORD, N.J. , July 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), to...
Citius Oncology Announces Pricing of $9.0 Million Public Offering
CRANFORD, N.J. , July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), to...
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™ CRANFORD, N.J. , July 15, 2025 /PRNew...
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
CRANFORD, N.J. , June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR...
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
CRANFORD, N.J. , May 14, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercial...
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
CEO Leonard Mazur to present on Thursday, June 5, 2025, at 3:10 pm ET CRANFORD, N.J. , May 5, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and its oncology subsidiary, Citius Oncol...
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
CRANFORD, N.J. , Feb. 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercializ...
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
CRANFORD, N.J. , Feb. 14, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercia...
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
Permanent J-Code (J9161) expected to be effective April 1, 2025 LYMPHIR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage...
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
CRANFORD, N.J. , Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today ...
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
CRANFORD, N.J. , Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (...
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercia...